Colorectal Cancer
Conditions
Keywords
SOT101, SO-C101, Cetuximab, Colorectal cancer, AURELIO-05, Nanrilkefusp alfa
Brief summary
The primary objective of the study is to estimate the antitumor efficacy of nanrilkefusp alfa (SOT101) in combination with cetuximab in RAS wild-type colorectal cancer.
Interventions
Subcutaneous (SC) injection
DRUGCetuximab
Intravenous (IV) infusion via peripheral or central venous line
Sponsors
SOTIO Biotech AG
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Study SC105 (AURELIO-05) was a phase 2, open-label, single-arm, multicenter study of nanrilkefusp alfa in combination with cetuximab with an initial safety run-in with 3+3 safety cohorts. Two safety cohorts were implemented. The main cohort was not opened.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
\*Type of patients\* 1. ≥18 years of age on the day of signing informed consent 2. Ability to understand and sign written informed consent to participate in the study 3. Provides written informed consent for the study 4. Life expectancy \>6 months \*Disease characteristics\* 5. Histologically or cytologically confirmed advanced and/or metastatic colorectal cancer 6. RAS wild type as confirmed by: * locally performed US Food and Drug Administration (FDA)-approved test or an experienced local laboratory using validated test methods for the detection, based on tumor biopsy or * locally performed ctDNA assessment including at least mutations in exon 2 (G12D, G12V, G12C, G12S, G12A, G12R, G13D) and determined by a laboratory using validated test methods * samples must be taken within 3 months prior to first study administration 7. Patients who are relapsed/refractory or intolerant to prior treatment with irinotecan- and oxaliplatin-containing chemotherapy 8. Have at least one measurable lesion according to RECIST 1.1 9. Eastern Cooperative Oncology Group (ECOG) performance score 0-2 10. Must have recovered from all AEs due to previous therapies to grade ≤1 toxicity (excluding alopecia) \*Organ function: Have adequate organ function as defined below. Specimens must be collected within 7 days prior to the start of study treatment.\* 11. Hematology: 11.1. Absolute neutrophil count ≥1,500/µL 11.2. Platelets ≥100,000/µL 11.3. Hemoglobin ≥9.0 g/dL (criteria must be met without packed red blood cell transfusion within the prior 2 weeks; patients can be on stable dose of erythropoietin \[≥3 months\]) 12. Renal function: Creatinine clearance rate ≥50 mL/min as calculated using Cockcroft-Gault equation 13. Hepatic function: ALT/AST ≤2.5× upper limit of normal (ULN) and total bilirubin ≤2×ULN in patients without liver metastasis (benign hereditary hyperbilirubinemias, e.g., Gilbert's syndrome, are permitted if total bilirubin \<3 mg/dL). In patients with liver metastasis, ALT/AST ≤5×ULN is allowed but total bilirubin must be ≤2×ULN. 14. Prothrombin time and activated partial thromboplastin time ≤1.5×ULN \*Hepatitis\* 15. A locally performed hepatitis B (HBV) test is required during screening. Patients who are HBV surface antigen positive are eligible if they have received HBV anti-viral therapy for at least 4 weeks and have undetectable HBV viral load before study entry (ICF signature). Patients should remain on anti-viral therapy throughout study treatment and follow local guidelines for HBV anti-viral therapy post completion of study treatments. 16. A locally performed hepatitis C (HCV) test is required during screening. Patients with history of HCV infection are eligible if HCV viral load is undetectable at screening. Patients must have completed anti-viral therapy at least 4 weeks before study entry (ICF signature). \*Special requirements for contraception\* 17. A female patient is eligible to participate if she is not pregnant, not breastfeeding, and one of the following conditions applies: 17.1. Not a woman of childbearing potential (WOCBP). A WOCBP is defined as fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy, and bilateral oophorectomy. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone level in the postmenopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy. However, in the absence of 12 months of amenorrhea, a single follicle stimulating hormone measurement is insufficient. 17.2. A WOCBP who agrees to use a highly effective contraceptive method during the treatment period and for at least 60 days after the last dose of cetuximab or at least 30 days after last dose of nanrilkefusp alfa, whichever is later. A WOCBP can only be included after a negative serum pregnancy test at screening within 7 days before day 1 of cycle 1. 18. Male patients must agree to use a condom during the treatment period and for at least 60 days after the last dose of cetuximab or at least 30 days after last dose of nanrilkefusp alfa, whichever is later.
Exclusion criteria
\*Prior/concomitant therapy\* 1. Prior exposure to drugs that are agonists of IL-2 or IL-15 2. Therapy with cetuximab within 3 months prior to ICF signature or patients who had progressive disease as best response to prior cetuximab-containing regimen 3. Prior systemic anti-cancer therapies, including investigational agents before study entry (ICF signature): 3.1. Less than 3 weeks or 5 half lives (whichever shorter) for anti-cancer treatments 3.2. Less than 4 weeks from major surgeries and not recovered adequately from the procedure and/or any complications from the surgery 4. Has received more than 4 prior lines of systemic anticancer treatment 5. Has received prior radiotherapy within 2 weeks of the start of study treatments. A 1-week radiation-free period is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-central nervous system disease. Patients must have recovered from all radiation-related toxicities and not require corticosteroids. 6. Has received a live or live-attenuated vaccine within 30 days prior to the first dose of study treatments \*Prior/concurrent clinical study experience\* 7. Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 3 weeks or 5 half lives (whichever longer) before study entry (ICF signature). Patients who have entered the follow-up phase of an investigational study may participate as long as it has been 3 weeks or 5 half lives (whichever longer) after the last dose of the previous investigational agent. \*Medical conditions\* 8. Patients with known BRAF mutations 9. Clinically significant cardiac abnormalities including prior history of any of the following: 9.1. Cardiomyopathy, with left ventricular ejection fraction lower than the lower limit of the institutional normal range at screening 9.2. Congestive heart failure of New York Heart Association grade ≥2 9.3. History of clinically significant (i.e., active) atherosclerotic cardiovascular disease, specifically myocardial infarction, unstable angina, cerebrovascular accident within 6 months prior to the first dose of study treatments, and any history of coronary heart disease and clinically significant peripheral and/or carotid artery disease 9.4. Prolongation of QTcF \>450 msec; history or family history of congenital long QT syndrome 9.5. Uncontrolled cardiac arrhythmia requiring medication 10. Uncontrolled hypertension defined as systolic blood pressure \>160 mmHg, diastolic blood pressure \>110 mmHg. Patients with uncontrolled hypertension should be medically managed on a stable regimen to control hypertension prior to study entry (ICF signature). 11. Has a clinical diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatments. Systemic steroid pretreatment prior to cetuximab infusion according to local guidelines is permitted. 12. History of or serology positive for HIV. A locally performed HIV test is required during screening. 13. Has a known additional malignancy that is progressing or has required active treatment within the past 5 years. Patients with basal cell carcinoma of the skin or carcinoma in situ (e.g., breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are eligible. 14. Has known active central nervous system metastases and/or carcinomatous meningitis. Patients with previously treated brain metastases may participate provided they are radiologically stable, i.e., without evidence of progression for at least 4 weeks confirmed during screening. 15. Has an active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed. 16. Has an active infection requiring systemic therapy 17. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study, or is not in the best interest of the patient to participate, in the opinion of the treating investigator 18. Has a known psychiatric or substance abuse disorder that would interfere with the patient's ability to cooperate with the requirements of the study 19. History of hypersensitivity to any component of cetuximab or to compounds of similar biological or chemical composition of nanrilkefusp alfa and/or the excipients contained in the study drug formulations
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Objective Response Rate According to Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1) | Day 1 up to approximately 1 year 2 months | Objective response rate according to RECIST 1.1 was defined as the proportion of participants with complete response according to RECIST 1.1 or partial response according to RECIST 1.1 for target lesions and assessed by CT/MRI. Participants with missing data were considered non-responders. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Best Overall Response According to RECIST 1.1: Number of Participants With Complete Response | Day 1 up to approximately 1 year 5 months | The best overall response according to RECIST 1.1 was defined as the best response from the start of study treatment until the first documented disease progression, death, or start of new anti-cancer therapy for target lesions and assessed by CT/MRI. |
| Best Overall Response According to RECIST 1.1: Number of Participants With Partial Response | Day 1 up to approximately 1 year 5 months | The best overall response according to RECIST 1.1 was defined as the best response from the start of study treatment until the first documented disease progression, death, or start of new anti-cancer therapy for target lesions and assessed by CT/MRI. |
| Best Overall Response According to RECIST 1.1: Number of Participants With Stable Disease | Day 1 up to approximately 1 year 5 months | The best overall response according to RECIST 1.1 was defined as the best response from the start of study treatment until the first documented disease progression, death, or start of new anti-cancer therapy for target lesions and assessed by CT/MRI. Stable disease according to RECIST 1.1 had to last at least 6 weeks from the start of study treatment. If not, at least 1 follow-up scan was required to declare stable disease. |
| Best Overall Response According to RECIST 1.1: Number of Participants With Progressive Disease | Day 1 up to approximately 1 year 5 months | The best overall response according to RECIST 1.1 was defined as the best response from the start of study treatment until the first documented disease progression, death, or start of new anti-cancer therapy for target lesions and assessed by CT/MRI. |
| Best Overall Response According to iRECIST: Number of Participants With Complete Response | Day 1 up to approximately 1 year 5 months | The best overall response according to iRECIST was defined as the best response from the start of study treatment until the first documented disease progression, death, or start of new anti-cancer therapy for target lesions and assessed by CT/MRI. |
| Best Overall Response According to iRECIST: Number of Participants With Partial Response | Day 1 up to approximately 1 year 5 months | The best overall response according to iRECIST was defined as the best response from the start of study treatment until the first documented disease progression, death, or start of new anti-cancer therapy for target lesions and assessed by CT/MRI. |
| Best Overall Response According to iRECIST: Number of Participants With Stable Disease | Day 1 up to approximately 1 year 5 months | The best overall response according to iRECIST was defined as the best response from the start of study treatment until the first documented disease progression, death, or start of new anti-cancer therapy for target lesions and assessed by CT/MRI. Stable disease according to iRECIST had to last at least 6 weeks from the start of study treatment. If not, at least 1 follow-up scan was required to declare stable disease. |
| Best Overall Response According to iRECIST: Number of Participants With Unconfirmed Progressive Disease | Day 1 up to approximately 1 year 5 months | The best overall response according to iRECIST was defined as the best response from the start of study treatment until the first documented disease progression, death, or start of new anti-cancer therapy for target lesions and assessed by CT/MRI. |
| Best Overall Response According to iRECIST: Number of Participants With Confirmed Progressive Disease | Day 1 up to approximately 1 year 5 months | The best overall response according to iRECIST was defined as the best response from the start of study treatment until the first documented disease progression, death, or start of new anti-cancer therapy for target lesions and assessed by CT/MRI. |
| Duration of Response According to RECIST 1.1 | Day 1 up to approximately 1 year 5 months | Duration of response according to RECIST 1.1 was defined as time to disease progression for participants with partial response or complete response according to RECIST 1.1. |
| Duration of Response According to iRECIST | Day 1 up to approximately 1 year 5 months | Duration of response according to iRECIST was defined as time to disease progression for participants with partial response or complete response according to iRECIST. |
| Clinical Benefit Rate According to RECIST 1.1 | Day 1 up to approximately 1 year 5 months | Clinical benefit rate according to RECIST 1.1 was defined as the number of partial responses, complete responses, and stable disease according to RECIST 1.1. Stable disease had to last at least 6 weeks from the start of study treatment. If not, at least 1 follow-up scan was required to declare stable disease. Participants with missing data were considered non-responders. |
| Clinical Benefit Rate According to iRECIST | Day 1 up to approximately 1 year 5 months | Clinical benefit rate according to iRECIST was defined as the number of partial responses, complete responses, and stable disease according to iRECIST. Stable disease had to last at least 6 weeks from the start of study treatment. If not, at least 1 follow-up scan was required to declare stable disease. Participants with missing data were considered non-responders. |
| Progression-free Survival According to RECIST 1.1 | Day 1 up to approximately 1 year 5 months | Progression-free survival according to RECIST 1.1 was defined as the time from the first day of study treatment to the first date of radiological disease progression according to RECIST 1.1 or death. |
| Objective Response Rate According to RECIST for Immune-based Therapeutics (iRECIST) | Day 1 up to approximately 1 year 5 months | Objective response rate according to iRECIST was defined as the proportion of participants with complete response according to iRECIST or partial response according to iRECIST for target lesions and assessed by CT/MRI. Participants with missing data were considered non-responders. |
| Time to Response According to RECIST 1.1 | Day 1 up to approximately 1 year 5 months | Time to response according to RECIST 1.1 was defined as the time from the first day of study treatment to the first date of partial response or complete response according to RECIST 1.1. Participants with missing data were censored at the last assessment date, date of death, or date of eligibility (for incomplete or missing baseline tumor assessments), whichever occurred last. |
| Time to Response According to iRECIST | Day 1 up to approximately 1 year 5 months | Time to response according to iRECIST was defined as the time from the first day of study treatment to the first date of partial response or complete response according to iRECIST. Participants with missing data were censored at the last assessment date, date of death, or date of eligibility (for incomplete or missing baseline tumor assessments), whichever occurred last. |
| Time to Progression According to RECIST 1.1 | Day 1 up to approximately 1 year 5 months | Time to progression according to RECIST 1.1 was defined as the time from the first day of study treatment to the first date of radiological disease progression according to RECIST 1.1. |
| Time to Progression According to iRECIST | Day 1 up to approximately 1 year 5 months | Time to progression according to iRECIST was defined as the time from the first day of study treatment to the first date of radiological disease progression according to iRECIST. |
| Number of Participants With Treatment-emergent Adverse Events | Day 1 up to approximately 1 year 5 months | A treatment-emergent adverse event is defined as an adverse event that started or worsened at or after the start of study treatment. |
| Number of Participants With Clinical Laboratory Test Abnormalities (Coagulation, Hematology, Clinical Chemistry and Urinalysis) | Day 1 up to approximately 1 year 5 months | The following laboratory parameters will be assessed: Coagulation: prothrombin time, activated partial thromboplastin time, international normalized ratio, D-dimer, and fibrinogen Hematology: hemoglobin, glycated hemoglobin at screening, hematocrit, red blood cell count, reticulocytes, white blood cell count (with full differentiation), absolute lymphocyte count, and platelet count Clinical chemistry: Na, K, Cl, phosphate, Mg, Ca, albumin, total protein, ALT, AST, bilirubin (direct, total), alkaline phosphatase, lactate dehydrogenase, creatinine clearance calculated by the Cockcroft-Gault formula, creatinine, glucose (preferably fasting), urea or blood urea nitrogen, cholesterol, triglyceride, C-reactive protein, uric acid, amylase, and lipase Urinalysis: pH, glucose, protein, bilirubin, urobilinogen. Microscopic examination (mandated only if clinically indicated): red blood cell count, white blood cell count, epithelial cells, bacteria |
| Number of Participants With Vital Signs Abnormalities | Day 1 up to approximately 1 year 5 months | The following vital signs parameters will be assessed: Blood pressure (systolic and diastolic, after ≥5 minutes of rest), body temperature, and heart rate |
| Number of Participants With Electrocardiography Abnormalities | Day 1 up to approximately 1 year 5 months | Standard 12-lead electrocardiography was evaluated locally. |
| Number of Participants With Dose-limiting Toxicities (DLTs) | Through Cycle 1 (21 days) | The following adverse events as per NCI CTCAE version 5.0 were considered dose-limiting toxicities: * All grade 5 events not clearly related to disease progression or any other causes * Any grade 3 or higher non-hematologic toxicity regardless of duration; exceptions: * Grade 3 nausea, vomiting, or diarrhea that could be controlled within 72 hours * Grade 3 fatigue lasting less than 5 days * Grade 3 or higher correctable electrolyte abnormalities lasting less than 72 hours and not associated with clinical complications * Grade 3 or higher serum amylase or lipase not associated with clinical manifestations of pancreatitis * Grade 3 AST or ALT increase or grade 3 blood bilirubin increase lasting 5 days or less * Hy's law cases * Hematologic DLTs: * Grade 4 decreased neutrophil count or decreased platelet count lasting more than 7 days * Febrile neutropenia * Grade 3 or higher decreased platelet count with bleeding |
| Characterization of Area Under the Curve of Nanrilkefusp Alfa | Day 1 of Cycle 1 | At 9 µg/kg nanrilkefusp alfa on Day 1 of Cycle 1 |
| Characterization of Maximum Concentration of Nanrilkefusp Alfa on Day 1 of Cycle 1 | Day 1 of Cycle 1 | At 9 µg/kg nanrilkefusp alfa |
| Characterization of Time to Maximum Concentration of Nanrilkefusp Alfa on Day 1 of Cycle 1 | Day 1 of Cycle 1 | At 9 µg/kg nanrilkefusp alfa |
| Characterization of Pre-dose Concentration of Nanrilkefusp Alfa on Day 1 of Cycle 1 | Day 1 of Cycle 1 | At 9 µg/kg nanrilkefusp alfa |
| Incidence of Treatment-induced Anti-drug Antibodies Against Nanrilkefusp Alfa | Day 1 until 30 (±2) days after the last dose of nanrilkefusp alfa, up to approximately 1 year 5 months | At 9 µg/kg and 12 µg/kg nanrilkefusp alfa |
| Progression-free Survival According to iRECIST | Day 1 up to approximately 1 year 5 months | Progression-free survival according to iRECIST was defined as the time from the first day of study treatment to the first date of radiological disease progression according to iRECIST or death. |
Countries
Belgium, France, Spain
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Nanrilkefusp Alfa and Cetuximab Participants were treated with nanrilkefusp alfa (safety cohort 1: 14 participants with 9 µg/kg nanrilkefusp alfa; safety cohort 2: 2 participants with 12 µg/kg nanrilkefusp alfa) in combination with cetuximab. Per statistical considerations outlined in the trial Protocol and Statistical Analysis Plan, all patients were analyzed within pre-specified populations across the entire trial. There was no plan to analyze cohorts separately; therefore, results are presented in aggregate. The trial was a single-arm design, not a classic dose-escalation study, as the RP2D (12 µg/kg) had been established in a prior trial (NCT04234113). The 9 µg/kg dose was a safety cohort allowing one-way crossover to 12 µg/kg.
Nanrilkefusp alfa treatment was administered on day 1 (from cycle 2 onwards, ±1 day), day 2 (±1 day), day 8 (±1 day), and day 9 (±1 day) of each 21-day cycle. Cetuximab treatment was administered on day 1 (from cycle 2 onwards, ±1 day), day 8 (±1 day), and day 15 (±1 day) of each 21-day cycle; on day 1 and day 8, cetuximab infusion started within 30 minutes after nanrilkefusp alfa administration. | 16 |
| Total | 16 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Safety Cohort 1 | Death | 7 | 0 |
| Safety Cohort 1 | Study terminated by sponsor | 7 | 0 |
| Safety Cohort 2 | Death | 0 | 1 |
| Safety Cohort 2 | Study terminated by sponsor | 0 | 1 |
Baseline characteristics
| Characteristic | Nanrilkefusp Alfa and Cetuximab |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 5 Participants |
| Age, Categorical Between 18 and 65 years | 11 Participants |
| Age, Continuous | 60 years |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 12 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 4 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 4 Participants |
| Race (NIH/OMB) White | 12 Participants |
| Region of Enrollment Belgium | 7 participants |
| Region of Enrollment France | 3 participants |
| Region of Enrollment Spain | 6 participants |
| Sex: Female, Male Female | 6 Participants |
| Sex: Female, Male Male | 10 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 7 / 14 | 1 / 2 |
| other Total, other adverse events | 14 / 14 | 2 / 2 |
| serious Total, serious adverse events | 7 / 14 | 1 / 2 |
Outcome results
Primary
Objective Response Rate According to Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1)
Objective response rate according to RECIST 1.1 was defined as the proportion of participants with complete response according to RECIST 1.1 or partial response according to RECIST 1.1 for target lesions and assessed by CT/MRI. Participants with missing data were considered non-responders.
Time frame: Day 1 up to approximately 1 year 2 months
Population: Per statistical considerations outlined in the trial Protocol and Statistical Analysis Plan, all patients were analyzed within pre-specified populations across the entire trial. There was no plan to analyze cohorts separately; therefore, results are presented in aggregate. The trial was a single-arm design, not a classic dose-escalation study, as the RP2D (12 µg/kg) had been established in a prior trial (NCT04234113). The 9 µg/kg dose was a safety cohort allowing one-way crossover to 12 µg/kg.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Nanrilkefusp Alfa and Cetuximab | Objective Response Rate According to Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1) | 0 percentage of participants |
Secondary
Best Overall Response According to iRECIST: Number of Participants With Complete Response
The best overall response according to iRECIST was defined as the best response from the start of study treatment until the first documented disease progression, death, or start of new anti-cancer therapy for target lesions and assessed by CT/MRI.
Time frame: Day 1 up to approximately 1 year 5 months
Population: Per statistical considerations outlined in the trial Protocol and Statistical Analysis Plan, all patients were analyzed within pre-specified populations across the entire trial. There was no plan to analyze cohorts separately; therefore, results are presented in aggregate. The trial was a single-arm design, not a classic dose-escalation study, as the RP2D (12 µg/kg) had been established in a prior trial (NCT04234113). The 9 µg/kg dose was a safety cohort allowing one-way crossover to 12 µg/kg.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Nanrilkefusp Alfa and Cetuximab | Best Overall Response According to iRECIST: Number of Participants With Complete Response | 0 Participants |
Secondary
Best Overall Response According to iRECIST: Number of Participants With Confirmed Progressive Disease
The best overall response according to iRECIST was defined as the best response from the start of study treatment until the first documented disease progression, death, or start of new anti-cancer therapy for target lesions and assessed by CT/MRI.
Time frame: Day 1 up to approximately 1 year 5 months
Population: Per statistical considerations outlined in the trial Protocol and Statistical Analysis Plan, all patients were analyzed within pre-specified populations across the entire trial. There was no plan to analyze cohorts separately; therefore, results are presented in aggregate. The trial was a single-arm design, not a classic dose-escalation study, as the RP2D (12 µg/kg) had been established in a prior trial (NCT04234113). The 9 µg/kg dose was a safety cohort allowing one-way crossover to 12 µg/kg.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Nanrilkefusp Alfa and Cetuximab | Best Overall Response According to iRECIST: Number of Participants With Confirmed Progressive Disease | 2 Participants |
Secondary
Best Overall Response According to iRECIST: Number of Participants With Partial Response
The best overall response according to iRECIST was defined as the best response from the start of study treatment until the first documented disease progression, death, or start of new anti-cancer therapy for target lesions and assessed by CT/MRI.
Time frame: Day 1 up to approximately 1 year 5 months
Population: Per statistical considerations outlined in the trial Protocol and Statistical Analysis Plan, all patients were analyzed within pre-specified populations across the entire trial. There was no plan to analyze cohorts separately; therefore, results are presented in aggregate. The trial was a single-arm design, not a classic dose-escalation study, as the RP2D (12 µg/kg) had been established in a prior trial (NCT04234113). The 9 µg/kg dose was a safety cohort allowing one-way crossover to 12 µg/kg.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Nanrilkefusp Alfa and Cetuximab | Best Overall Response According to iRECIST: Number of Participants With Partial Response | 0 Participants |
Secondary
Best Overall Response According to iRECIST: Number of Participants With Stable Disease
The best overall response according to iRECIST was defined as the best response from the start of study treatment until the first documented disease progression, death, or start of new anti-cancer therapy for target lesions and assessed by CT/MRI. Stable disease according to iRECIST had to last at least 6 weeks from the start of study treatment. If not, at least 1 follow-up scan was required to declare stable disease.
Time frame: Day 1 up to approximately 1 year 5 months
Population: Per statistical considerations outlined in the trial Protocol and Statistical Analysis Plan, all patients were analyzed within pre-specified populations across the entire trial. There was no plan to analyze cohorts separately; therefore, results are presented in aggregate. The trial was a single-arm design, not a classic dose-escalation study, as the RP2D (12 µg/kg) had been established in a prior trial (NCT04234113). The 9 µg/kg dose was a safety cohort allowing one-way crossover to 12 µg/kg.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Nanrilkefusp Alfa and Cetuximab | Best Overall Response According to iRECIST: Number of Participants With Stable Disease | 6 Participants |
Secondary
Best Overall Response According to iRECIST: Number of Participants With Unconfirmed Progressive Disease
The best overall response according to iRECIST was defined as the best response from the start of study treatment until the first documented disease progression, death, or start of new anti-cancer therapy for target lesions and assessed by CT/MRI.
Time frame: Day 1 up to approximately 1 year 5 months
Population: Per statistical considerations outlined in the trial Protocol and Statistical Analysis Plan, all patients were analyzed within pre-specified populations across the entire trial. There was no plan to analyze cohorts separately; therefore, results are presented in aggregate. The trial was a single-arm design, not a classic dose-escalation study, as the RP2D (12 µg/kg) had been established in a prior trial (NCT04234113). The 9 µg/kg dose was a safety cohort allowing one-way crossover to 12 µg/kg.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Nanrilkefusp Alfa and Cetuximab | Best Overall Response According to iRECIST: Number of Participants With Unconfirmed Progressive Disease | 5 Participants |
Secondary
Best Overall Response According to RECIST 1.1: Number of Participants With Complete Response
The best overall response according to RECIST 1.1 was defined as the best response from the start of study treatment until the first documented disease progression, death, or start of new anti-cancer therapy for target lesions and assessed by CT/MRI.
Time frame: Day 1 up to approximately 1 year 5 months
Population: Per statistical considerations outlined in the trial Protocol and Statistical Analysis Plan, all patients were analyzed within pre-specified populations across the entire trial. There was no plan to analyze cohorts separately; therefore, results are presented in aggregate. The trial was a single-arm design, not a classic dose-escalation study, as the RP2D (12 µg/kg) had been established in a prior trial (NCT04234113). The 9 µg/kg dose was a safety cohort allowing one-way crossover to 12 µg/kg.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Nanrilkefusp Alfa and Cetuximab | Best Overall Response According to RECIST 1.1: Number of Participants With Complete Response | 0 Participants |
Secondary
Best Overall Response According to RECIST 1.1: Number of Participants With Partial Response
The best overall response according to RECIST 1.1 was defined as the best response from the start of study treatment until the first documented disease progression, death, or start of new anti-cancer therapy for target lesions and assessed by CT/MRI.
Time frame: Day 1 up to approximately 1 year 5 months
Population: Per statistical considerations outlined in the trial Protocol and Statistical Analysis Plan, all patients were analyzed within pre-specified populations across the entire trial. There was no plan to analyze cohorts separately; therefore, results are presented in aggregate. The trial was a single-arm design, not a classic dose-escalation study, as the RP2D (12 µg/kg) had been established in a prior trial (NCT04234113). The 9 µg/kg dose was a safety cohort allowing one-way crossover to 12 µg/kg.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Nanrilkefusp Alfa and Cetuximab | Best Overall Response According to RECIST 1.1: Number of Participants With Partial Response | 0 Participants |
Secondary
Best Overall Response According to RECIST 1.1: Number of Participants With Progressive Disease
The best overall response according to RECIST 1.1 was defined as the best response from the start of study treatment until the first documented disease progression, death, or start of new anti-cancer therapy for target lesions and assessed by CT/MRI.
Time frame: Day 1 up to approximately 1 year 5 months
Population: Per statistical considerations outlined in the trial Protocol and Statistical Analysis Plan, all patients were analyzed within pre-specified populations across the entire trial. There was no plan to analyze cohorts separately; therefore, results are presented in aggregate. The trial was a single-arm design, not a classic dose-escalation study, as the RP2D (12 µg/kg) had been established in a prior trial (NCT04234113). The 9 µg/kg dose was a safety cohort allowing one-way crossover to 12 µg/kg.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Nanrilkefusp Alfa and Cetuximab | Best Overall Response According to RECIST 1.1: Number of Participants With Progressive Disease | 7 Participants |
Secondary
Best Overall Response According to RECIST 1.1: Number of Participants With Stable Disease
The best overall response according to RECIST 1.1 was defined as the best response from the start of study treatment until the first documented disease progression, death, or start of new anti-cancer therapy for target lesions and assessed by CT/MRI. Stable disease according to RECIST 1.1 had to last at least 6 weeks from the start of study treatment. If not, at least 1 follow-up scan was required to declare stable disease.
Time frame: Day 1 up to approximately 1 year 5 months
Population: Per statistical considerations outlined in the trial Protocol and Statistical Analysis Plan, all patients were analyzed within pre-specified populations across the entire trial. There was no plan to analyze cohorts separately; therefore, results are presented in aggregate. The trial was a single-arm design, not a classic dose-escalation study, as the RP2D (12 µg/kg) had been established in a prior trial (NCT04234113). The 9 µg/kg dose was a safety cohort allowing one-way crossover to 12 µg/kg.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Nanrilkefusp Alfa and Cetuximab | Best Overall Response According to RECIST 1.1: Number of Participants With Stable Disease | 6 Participants |
Secondary
Characterization of Area Under the Curve of Nanrilkefusp Alfa
At 9 µg/kg nanrilkefusp alfa on Day 1 of Cycle 1
Time frame: Day 1 of Cycle 1
Population: Per statistical considerations outlined in the trial Protocol and Statistical Analysis Plan, all patients were analyzed within pre-specified populations across the entire trial. There was no plan to analyze cohorts separately; therefore, results are presented in aggregate. The trial was a single-arm design, not a classic dose-escalation study, as the RP2D (12 µg/kg) had been established in a prior trial (NCT04234113). The 9 µg/kg dose was a safety cohort allowing one-way crossover to 12 µg/kg.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Nanrilkefusp Alfa and Cetuximab | Characterization of Area Under the Curve of Nanrilkefusp Alfa | 37.1 h*ng/mL |
Secondary
Characterization of Maximum Concentration of Nanrilkefusp Alfa on Day 1 of Cycle 1
At 9 µg/kg nanrilkefusp alfa
Time frame: Day 1 of Cycle 1
Population: Per statistical considerations outlined in the trial Protocol and Statistical Analysis Plan, all patients were analyzed within pre-specified populations across the entire trial. There was no plan to analyze cohorts separately; therefore, results are presented in aggregate. The trial was a single-arm design, not a classic dose-escalation study, as the RP2D (12 µg/kg) had been established in a prior trial (NCT04234113). The 9 µg/kg dose was a safety cohort allowing one-way crossover to 12 µg/kg.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Nanrilkefusp Alfa and Cetuximab | Characterization of Maximum Concentration of Nanrilkefusp Alfa on Day 1 of Cycle 1 | 3.56 ng/mL |
Secondary
Characterization of Pre-dose Concentration of Nanrilkefusp Alfa on Day 1 of Cycle 1
At 9 µg/kg nanrilkefusp alfa
Time frame: Day 1 of Cycle 1
Population: Per statistical considerations outlined in the trial Protocol and Statistical Analysis Plan, all patients were analyzed within pre-specified populations across the entire trial. There was no plan to analyze cohorts separately; therefore, results are presented in aggregate. The trial was a single-arm design, not a classic dose-escalation study, as the RP2D (12 µg/kg) had been established in a prior trial (NCT04234113). The 9 µg/kg dose was a safety cohort allowing one-way crossover to 12 µg/kg.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Nanrilkefusp Alfa and Cetuximab | Characterization of Pre-dose Concentration of Nanrilkefusp Alfa on Day 1 of Cycle 1 | 0.404 ng/mL |
Secondary
Characterization of Time to Maximum Concentration of Nanrilkefusp Alfa on Day 1 of Cycle 1
At 9 µg/kg nanrilkefusp alfa
Time frame: Day 1 of Cycle 1
Population: Per statistical considerations outlined in the trial Protocol and Statistical Analysis Plan, all patients were analyzed within pre-specified populations across the entire trial. There was no plan to analyze cohorts separately; therefore, results are presented in aggregate. The trial was a single-arm design, not a classic dose-escalation study, as the RP2D (12 µg/kg) had been established in a prior trial (NCT04234113). The 9 µg/kg dose was a safety cohort allowing one-way crossover to 12 µg/kg.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Nanrilkefusp Alfa and Cetuximab | Characterization of Time to Maximum Concentration of Nanrilkefusp Alfa on Day 1 of Cycle 1 | 6.21 hours |
Secondary
Clinical Benefit Rate According to iRECIST
Clinical benefit rate according to iRECIST was defined as the number of partial responses, complete responses, and stable disease according to iRECIST. Stable disease had to last at least 6 weeks from the start of study treatment. If not, at least 1 follow-up scan was required to declare stable disease. Participants with missing data were considered non-responders.
Time frame: Day 1 up to approximately 1 year 5 months
Population: Per statistical considerations outlined in the trial Protocol and Statistical Analysis Plan, all patients were analyzed within pre-specified populations across the entire trial. There was no plan to analyze cohorts separately; therefore, results are presented in aggregate. The trial was a single-arm design, not a classic dose-escalation study, as the RP2D (12 µg/kg) had been established in a prior trial (NCT04234113). The 9 µg/kg dose was a safety cohort allowing one-way crossover to 12 µg/kg.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Nanrilkefusp Alfa and Cetuximab | Clinical Benefit Rate According to iRECIST | 37.5 percentage of participants |
Secondary
Clinical Benefit Rate According to RECIST 1.1
Clinical benefit rate according to RECIST 1.1 was defined as the number of partial responses, complete responses, and stable disease according to RECIST 1.1. Stable disease had to last at least 6 weeks from the start of study treatment. If not, at least 1 follow-up scan was required to declare stable disease. Participants with missing data were considered non-responders.
Time frame: Day 1 up to approximately 1 year 5 months
Population: Per statistical considerations outlined in the trial Protocol and Statistical Analysis Plan, all patients were analyzed within pre-specified populations across the entire trial. There was no plan to analyze cohorts separately; therefore, results are presented in aggregate. The trial was a single-arm design, not a classic dose-escalation study, as the RP2D (12 µg/kg) had been established in a prior trial (NCT04234113). The 9 µg/kg dose was a safety cohort allowing one-way crossover to 12 µg/kg.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Nanrilkefusp Alfa and Cetuximab | Clinical Benefit Rate According to RECIST 1.1 | 37.5 percentage of participants |
Secondary
Duration of Response According to iRECIST
Duration of response according to iRECIST was defined as time to disease progression for participants with partial response or complete response according to iRECIST.
Time frame: Day 1 up to approximately 1 year 5 months
Population: As outlined in the trial Protocol and Statistical Analysis Plan, patients were analyzed within pre-specified populations across the trial. There was no plan to analyze cohorts separately; results are presented in aggregate. The trial was a single-arm design, not a dose-escalation study; the RP2D (12 µg/kg) was established in a prior trial (NCT04234113). The 9 µg/kg dose was a safety cohort with one-way crossover to 12 µg/kg.~No participant had a PR or CR per iRECIST; DoR data were not collected
Secondary
Duration of Response According to RECIST 1.1
Duration of response according to RECIST 1.1 was defined as time to disease progression for participants with partial response or complete response according to RECIST 1.1.
Time frame: Day 1 up to approximately 1 year 5 months
Population: As outlined in the trial Protocol and Statistical Analysis Plan, patients were analyzed within pre-specified populations across the trial. There was no plan to analyze cohorts separately; results are presented in aggregate. The trial was a single-arm design, not a dose-escalation study; the RP2D (12 µg/kg) was established in a prior trial (NCT04234113). The 9 µg/kg dose was a safety cohort with one-way crossover to 12 µg/kg.~No participant had a PR or CR per RECIST; DoR data were not collected.
Secondary
Incidence of Treatment-induced Anti-drug Antibodies Against Nanrilkefusp Alfa
At 9 µg/kg and 12 µg/kg nanrilkefusp alfa
Time frame: Day 1 until 30 (±2) days after the last dose of nanrilkefusp alfa, up to approximately 1 year 5 months
Population: Per statistical considerations outlined in the trial Protocol and Statistical Analysis Plan, all patients were analyzed within pre-specified populations across the entire trial. There was no plan to analyze cohorts separately; therefore, results are presented in aggregate. The trial was a single-arm design, not a classic dose-escalation study, as the RP2D (12 µg/kg) had been established in a prior trial (NCT04234113). The 9 µg/kg dose was a safety cohort allowing one-way crossover to 12 µg/kg.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Nanrilkefusp Alfa and Cetuximab | Incidence of Treatment-induced Anti-drug Antibodies Against Nanrilkefusp Alfa | 5 Participants |
Secondary
Number of Participants With Clinical Laboratory Test Abnormalities (Coagulation, Hematology, Clinical Chemistry and Urinalysis)
The following laboratory parameters will be assessed: Coagulation: prothrombin time, activated partial thromboplastin time, international normalized ratio, D-dimer, and fibrinogen Hematology: hemoglobin, glycated hemoglobin at screening, hematocrit, red blood cell count, reticulocytes, white blood cell count (with full differentiation), absolute lymphocyte count, and platelet count Clinical chemistry: Na, K, Cl, phosphate, Mg, Ca, albumin, total protein, ALT, AST, bilirubin (direct, total), alkaline phosphatase, lactate dehydrogenase, creatinine clearance calculated by the Cockcroft-Gault formula, creatinine, glucose (preferably fasting), urea or blood urea nitrogen, cholesterol, triglyceride, C-reactive protein, uric acid, amylase, and lipase Urinalysis: pH, glucose, protein, bilirubin, urobilinogen. Microscopic examination (mandated only if clinically indicated): red blood cell count, white blood cell count, epithelial cells, bacteria
Time frame: Day 1 up to approximately 1 year 5 months
Population: Per statistical considerations outlined in the trial Protocol and Statistical Analysis Plan, all patients were analyzed within pre-specified populations across the entire trial. There was no plan to analyze cohorts separately; therefore, results are presented in aggregate. The trial was a single-arm design, not a classic dose-escalation study, as the RP2D (12 µg/kg) had been established in a prior trial (NCT04234113). The 9 µg/kg dose was a safety cohort allowing one-way crossover to 12 µg/kg.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Nanrilkefusp Alfa and Cetuximab | Number of Participants With Clinical Laboratory Test Abnormalities (Coagulation, Hematology, Clinical Chemistry and Urinalysis) | 11 Participants |
Secondary
Number of Participants With Dose-limiting Toxicities (DLTs)
The following adverse events as per NCI CTCAE version 5.0 were considered dose-limiting toxicities: * All grade 5 events not clearly related to disease progression or any other causes * Any grade 3 or higher non-hematologic toxicity regardless of duration; exceptions: * Grade 3 nausea, vomiting, or diarrhea that could be controlled within 72 hours * Grade 3 fatigue lasting less than 5 days * Grade 3 or higher correctable electrolyte abnormalities lasting less than 72 hours and not associated with clinical complications * Grade 3 or higher serum amylase or lipase not associated with clinical manifestations of pancreatitis * Grade 3 AST or ALT increase or grade 3 blood bilirubin increase lasting 5 days or less * Hy's law cases * Hematologic DLTs: * Grade 4 decreased neutrophil count or decreased platelet count lasting more than 7 days * Febrile neutropenia * Grade 3 or higher decreased platelet count with bleeding
Time frame: Through Cycle 1 (21 days)
Population: Per statistical considerations outlined in the trial Protocol and Statistical Analysis Plan, all patients were analyzed within pre-specified populations across the entire trial. There was no plan to analyze cohorts separately; therefore, results are presented in aggregate. The trial was a single-arm design, not a classic dose-escalation study, as the RP2D (12 µg/kg) had been established in a prior trial (NCT04234113). The 9 µg/kg dose was a safety cohort allowing one-way crossover to 12 µg/kg.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Nanrilkefusp Alfa and Cetuximab | Number of Participants With Dose-limiting Toxicities (DLTs) | 0 Participants |
Secondary
Number of Participants With Electrocardiography Abnormalities
Standard 12-lead electrocardiography was evaluated locally.
Time frame: Day 1 up to approximately 1 year 5 months
Population: Per statistical considerations outlined in the trial Protocol and Statistical Analysis Plan, all patients were analyzed within pre-specified populations across the entire trial. There was no plan to analyze cohorts separately; therefore, results are presented in aggregate. The trial was a single-arm design, not a classic dose-escalation study, as the RP2D (12 µg/kg) had been established in a prior trial (NCT04234113). The 9 µg/kg dose was a safety cohort allowing one-way crossover to 12 µg/kg.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Nanrilkefusp Alfa and Cetuximab | Number of Participants With Electrocardiography Abnormalities | 1 Participants |
Secondary
Number of Participants With Treatment-emergent Adverse Events
A treatment-emergent adverse event is defined as an adverse event that started or worsened at or after the start of study treatment.
Time frame: Day 1 up to approximately 1 year 5 months
Population: Per statistical considerations outlined in the trial Protocol and Statistical Analysis Plan, all patients were analyzed within pre-specified populations across the entire trial. There was no plan to analyze cohorts separately; therefore, results are presented in aggregate. The trial was a single-arm design, not a classic dose-escalation study, as the RP2D (12 µg/kg) had been established in a prior trial (NCT04234113). The 9 µg/kg dose was a safety cohort allowing one-way crossover to 12 µg/kg.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Nanrilkefusp Alfa and Cetuximab | Number of Participants With Treatment-emergent Adverse Events | 16 Participants |
Secondary
Number of Participants With Vital Signs Abnormalities
The following vital signs parameters will be assessed: Blood pressure (systolic and diastolic, after ≥5 minutes of rest), body temperature, and heart rate
Time frame: Day 1 up to approximately 1 year 5 months
Population: Per statistical considerations outlined in the trial Protocol and Statistical Analysis Plan, all patients were analyzed within pre-specified populations across the entire trial. There was no plan to analyze cohorts separately; therefore, results are presented in aggregate. The trial was a single-arm design, not a classic dose-escalation study, as the RP2D (12 µg/kg) had been established in a prior trial (NCT04234113). The 9 µg/kg dose was a safety cohort allowing one-way crossover to 12 µg/kg.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Nanrilkefusp Alfa and Cetuximab | Number of Participants With Vital Signs Abnormalities | 11 Participants |
Secondary
Objective Response Rate According to RECIST for Immune-based Therapeutics (iRECIST)
Objective response rate according to iRECIST was defined as the proportion of participants with complete response according to iRECIST or partial response according to iRECIST for target lesions and assessed by CT/MRI. Participants with missing data were considered non-responders.
Time frame: Day 1 up to approximately 1 year 5 months
Population: Per statistical considerations outlined in the trial Protocol and Statistical Analysis Plan, all patients were analyzed within pre-specified populations across the entire trial. There was no plan to analyze cohorts separately; therefore, results are presented in aggregate. The trial was a single-arm design, not a classic dose-escalation study, as the RP2D (12 µg/kg) had been established in a prior trial (NCT04234113). The 9 µg/kg dose was a safety cohort allowing one-way crossover to 12 µg/kg.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Nanrilkefusp Alfa and Cetuximab | Objective Response Rate According to RECIST for Immune-based Therapeutics (iRECIST) | 0 percentage of participants |
Secondary
Progression-free Survival According to iRECIST
Progression-free survival according to iRECIST was defined as the time from the first day of study treatment to the first date of radiological disease progression according to iRECIST or death.
Time frame: Day 1 up to approximately 1 year 5 months
Population: Per statistical considerations outlined in the trial Protocol and Statistical Analysis Plan, all patients were analyzed within pre-specified populations across the entire trial. There was no plan to analyze cohorts separately; therefore, results are presented in aggregate. The trial was a single-arm design, not a classic dose-escalation study, as the RP2D (12 µg/kg) had been established in a prior trial (NCT04234113). The 9 µg/kg dose was a safety cohort allowing one-way crossover to 12 µg/kg.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Nanrilkefusp Alfa and Cetuximab | Progression-free Survival According to iRECIST | 2.7 months |
Secondary
Progression-free Survival According to RECIST 1.1
Progression-free survival according to RECIST 1.1 was defined as the time from the first day of study treatment to the first date of radiological disease progression according to RECIST 1.1 or death.
Time frame: Day 1 up to approximately 1 year 5 months
Population: Per statistical considerations outlined in the trial Protocol and Statistical Analysis Plan, all patients were analyzed within pre-specified populations across the entire trial. There was no plan to analyze cohorts separately; therefore, results are presented in aggregate. The trial was a single-arm design, not a classic dose-escalation study, as the RP2D (12 µg/kg) had been established in a prior trial (NCT04234113). The 9 µg/kg dose was a safety cohort allowing one-way crossover to 12 µg/kg.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Nanrilkefusp Alfa and Cetuximab | Progression-free Survival According to RECIST 1.1 | 2.7 months |
Secondary
Time to Progression According to iRECIST
Time to progression according to iRECIST was defined as the time from the first day of study treatment to the first date of radiological disease progression according to iRECIST.
Time frame: Day 1 up to approximately 1 year 5 months
Population: Per statistical considerations outlined in the trial Protocol and Statistical Analysis Plan, all patients were analyzed within pre-specified populations across the entire trial. There was no plan to analyze cohorts separately; therefore, results are presented in aggregate. The trial was a single-arm design, not a classic dose-escalation study, as the RP2D (12 µg/kg) had been established in a prior trial (NCT04234113). The 9 µg/kg dose was a safety cohort allowing one-way crossover to 12 µg/kg.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Nanrilkefusp Alfa and Cetuximab | Time to Progression According to iRECIST | 2.8 months |
Secondary
Time to Progression According to RECIST 1.1
Time to progression according to RECIST 1.1 was defined as the time from the first day of study treatment to the first date of radiological disease progression according to RECIST 1.1.
Time frame: Day 1 up to approximately 1 year 5 months
Population: Per statistical considerations outlined in the trial Protocol and Statistical Analysis Plan, all patients were analyzed within pre-specified populations across the entire trial. There was no plan to analyze cohorts separately; therefore, results are presented in aggregate. The trial was a single-arm design, not a classic dose-escalation study, as the RP2D (12 µg/kg) had been established in a prior trial (NCT04234113). The 9 µg/kg dose was a safety cohort allowing one-way crossover to 12 µg/kg.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Nanrilkefusp Alfa and Cetuximab | Time to Progression According to RECIST 1.1 | 2.8 months |
Secondary
Time to Response According to iRECIST
Time to response according to iRECIST was defined as the time from the first day of study treatment to the first date of partial response or complete response according to iRECIST. Participants with missing data were censored at the last assessment date, date of death, or date of eligibility (for incomplete or missing baseline tumor assessments), whichever occurred last.
Time frame: Day 1 up to approximately 1 year 5 months
Population: Per statistical considerations outlined in the trial Protocol and Statistical Analysis Plan, all patients were analyzed within pre-specified populations across the entire trial. There was no plan to analyze cohorts separately; therefore, results are presented in aggregate. The trial was a single-arm design, not a classic dose-escalation study, as the RP2D (12 µg/kg) had been established in a prior trial (NCT04234113). The 9 µg/kg dose was a safety cohort allowing one-way crossover to 12 µg/kg.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Nanrilkefusp Alfa and Cetuximab | Time to Response According to iRECIST | 0 months |
Secondary
Time to Response According to RECIST 1.1
Time to response according to RECIST 1.1 was defined as the time from the first day of study treatment to the first date of partial response or complete response according to RECIST 1.1. Participants with missing data were censored at the last assessment date, date of death, or date of eligibility (for incomplete or missing baseline tumor assessments), whichever occurred last.
Time frame: Day 1 up to approximately 1 year 5 months
Population: Per statistical considerations outlined in the trial Protocol and Statistical Analysis Plan, all patients were analyzed within pre-specified populations across the entire trial. There was no plan to analyze cohorts separately; therefore, results are presented in aggregate. The trial was a single-arm design, not a classic dose-escalation study, as the RP2D (12 µg/kg) had been established in a prior trial (NCT04234113). The 9 µg/kg dose was a safety cohort allowing one-way crossover to 12 µg/kg.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Nanrilkefusp Alfa and Cetuximab | Time to Response According to RECIST 1.1 | 0 months |